Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
trivalent inactivated influenza virus vaccine (2006-2007 formulation)
- Development stage
- Approved
- Lead developer
- Sanofi Pasteur
- Modality
- Vaccines & Immunotherapeutics
- Administration
- Intranasal
01
Overview
**Trivalent inactivated influenza virus vaccine (2006-2007 formulation)** is a seasonal, egg-derived inactivated influenza vaccine formulation used during the 2006-2007 Northern Hemisphere influenza season. It contained antigens representing influenza A/H1N1 A/New Caledonia/20/99, influenza A/H3N2 A/Wisconsin/67/2005, and influenza B B/Malaysia/2506/2004. As an inactivated vaccine, it presents viral surface antigens, principally hemagglutinin, to induce strain-specific humoral immune responses that can prevent influenza illness caused by antigenically related influenza A and B viruses. In NIAID-sponsored Phase 1 study NCT00436046, the commercially available vaccine was administered by intranasal instillation, alone or with type 1 interferon as a mucosal adjuvant, in healthy adults; this intranasal use was investigational and distinct from conventional intramuscular seasonal-vaccine administration. ([cdek.pharmacy.purdue.edu](https://cdek.pharmacy.purdue.edu/trial/NCT00436046/))
- Brand names
- FluarixAfluria
- Other names
- 2006-2007 trivalent inactivated influenza vaccine2006-2007 TIV
02
Targets
B-cell receptor and antibody repertoire recognizing influenza hemagglutinin and neuraminidaseTCR (T-cell receptor)PRR (Pattern recognition receptors)
Beyond the preview
Go deeper on trivalent inactivated influenza virus vaccine (2006-2007 formulation).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on trivalent inactivated influenza virus vaccine (2006-2007 formulation).